# C_2013165EN.01001301.xml

| 11.6.2013 | EN | Official Journal of the European Union | C 165/13 |
| --- | --- | --- | --- |

11.6.2013

EN

Official Journal of the European Union

C 165/13

---

Prior notification of a concentration

(Case COMP/M.6851 — Baxter International/Gambro)

(Text with EEA relevance)

2013/C 165/10

| 1. | On 3 June 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Baxter International Inc. (‘Baxter’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Gambro AB (‘Gambro’, Sweden) by way of purchase of shares. |
| --- | --- |

1.

On 3 June 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Baxter International Inc. (‘Baxter’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Gambro AB (‘Gambro’, Sweden) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Baxter: developing, manufacturing and marketing of products used in the treatment of patients suffering from haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Baxter: developing, manufacturing and marketing of products used in the treatment of patients suffering from haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions,

| — | for Gambro: developing, manufacturing and supply of products and therapies for haemodialysis, continuous renal replacement therapy, liver dialysis, myeloma kidney therapy, related water systems and other extracorporeal therapies for chronic and acute patients. |
| --- | --- |

—

for Gambro: developing, manufacturing and supply of products and therapies for haemodialysis, continuous renal replacement therapy, liver dialysis, myeloma kidney therapy, related water systems and other extracorporeal therapies for chronic and acute patients.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6851 — Baxter International/Gambro, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6851 — Baxter International/Gambro, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---